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The Cardiac Arrhythmia Suppression Trial (CAST) was a slut •~
designed to test the hypothesis that suppression of ventrierdar
premnture complexes after a myocardial infarction recoil Ins
prove survival. Preliminary results sh-ed that
suppression,
of
ventricular premature complexes with encainide and ileraimide
worsened sarvira
. and else CAST cautioned as the CAST-11 with
Tarkizine compared with its placebo,
The protocol for the CAST-I1 was changed toattempt to enroll
patients more likely to experience serious arrhythmiass . 'The
enrollment time was narrowed to d tc 90 days after myocardial
infarction; the qualifying ejection fraction was towered to <-0,40;
a higher dose of moriciroe could be used ; early titration itself eas
double-blind stun a placebo, and the definition of disqualifying
The initial results of lke Cardiac Arrhythmia Suppression
Trial (CAST) (1) led clinicians curing for patients with
arrhythmia' to question treatment strategies that had been
widely accepted, though not vnlidated
. The purpose of this
report is to sunuuarizc hew and why the dc--sign of the study
was -hanged for the continuation of the trial, coiled the
Cardiac Arrhythmia Suppression Trial-11 (CAS'T-11) .
The Cardiac Arrhythmia
Suppression Trial
(CAST) Hypothesis and Original Design
Two hypotheses were considered for testing in the Car-
diac Arrhythmia Suppression Trial. I) that drug nenrrnettr of
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ventricular larhycardia was changed to allure patients with more
serious arrh5thrnias to be entered into the trial .
The Cardiac Anhythmlu Seppressim Trial
.ll wail sandise.
quenlly terminated prematurely because 1) patients treated with
moricieine had an excessive cardiac mortality rate during the lot
2 weeks of exposure to the dog, and 2) there appeared to be tittle
chance of showing a long-term survival hesmhc from treatment
with mnricialne.
This report outlines the rationale behind the Cardiac Arrhyth-
mia Suppression Trial and the reasons for selection of We drugs
used in the CAST and CAST-11.
p .Am Coll Cordial 1992;19x894-S1
asymptomatic ventricular premature complexes in patients
after n myocardial infarction would improve survival, or
21 that drug-''oppression of asynntomatic ventricular prema-
ture corplexes would improve survival. These two hypoth-
eses'nad major implications for study design
. With the drug
trvownern
hypothesis, patients would simply be randomly
assigned to treatment with an antiarrhythmic drug or its
placebo ; they would he continued an long-term therapy to
examine the effect of the drug on survival, The drug aup-
preseInn hypothesis more closely mimicked clinical practice .
Analysis of Holler recordings would be required to show
that a drug had indeed suppressed ventricular premature
complexes adequately before a patient could be randomly
assigned to loot-term treatment with that agent or its pla-
cebo . Ultimately, it was decided to test the drug suppression
hypothesis in the CAST.
In the original design of the CAST, each patient's ven-
tricular premature comp ;
cxes were suppressed by an anti-
arrhythmic drug (selected randomly for the dose titralinn
phase), and the patient was then rendomizaal to treatment
with either the active drug that suppressed the ventricular
premature complexes or its matching placebo . Thus, the
design of the CAST identified -'responders" to a drug . who
were then randomized either to that drug or to its matching
placebo . Patients who had inadequate suppression of ven-
tricular premature complexes or who had proarrhy'thmic
0735 109"2,15 .00
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responses during the dose titration phase were entered into
various substudies and not considered cart of the main
Study
Because the increased risk for sudden arrhythmic death
in the presence of ventricular ectopic activity and Depressed
left ventricular function may persist lore after a tnvocarlial
-clioii
i2), the original entry window include! patients
6 days to 2 years after a myocardial infarction, and upper
limits for ejection fraction were sought to enroll a h'gh
risk
population . There was no lower limit on ejection fraction . If
the elapsed time since the myocardial infarction was long
(90 days to 2 years), the ejection fraction had to be -0 .40 for
the patient to be eligible. For patients with a more recent
myocardial infarction (6 in 89 days), the ejection fraction had
to be z0,55 . The rationale for this design was that the
highest risk for arrhythmic death is during the lest few
months after myocardial infarction. After the first few
months, the risk decreases and is minimal unless left ven-
tricular function is reduced • Therefore, patients who entered
the CAST late after myocardial infarction were required to
have a lower ejection fraction to maintain a sufficiently high
risk of sudden death that participants in this trial might
demonstrate benefit,
Patients with ?6 ventricular premature complexes/Iv were
entered in the CAST because it appeared [hat the risk of
arrhythmic events begins with I ventricular premature com-
plexth and increases to a plateau at a rate of >10 such
compkxes'h (5) .
The definition
of ventricular rachycardia for the CAST
allowed enrollment of patients thought to be at relatively
high risk
. The length of ventricular tachycardia defined to be
disqualifying was ?15 beats at a rate of >120 beats/min .
Patients with bundle bested block were also included in the
CAST .
Drug Selection for the CAST
The selection of nnaarrhythmic drugs for inclusion in the
CAST was based on the specific characteristics of the drugs
.~
the proposea pattern population and the requirements dic-
tated by the ventricularectopie activity suppression hypoth-
esis (a) . As with all secondary prevention tricks drug selec-
tion was based primarily on the relative risk/benefit ratio fnr
each drug
. Dependence an a single drug was not considered
to be desirable because the intent of the CAST was to test a
treatment strategy and not a specific drug.
In late 1906, during the planning phase of the CAST, the
Drug Selection and Titration Subcommittee reviewed cur-
rently available and investigntionai amierrhythmic agents for
poteutial inclusion in the trial . The criteria in Table I were
assessed for each drug. The Subcommittee also considered :
1) the total number of persons evaluated in clinical studies,
2) the total number of patients who had been evaluated for
drug safety and efficacy for > I year, and 3) the quality of the
data base in patients comparable to patients projected for
inclusion in the CAST.
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Tabt . 1 .
Criteria for Dr u6 Selection: lire Cardiac Arrhythmia
Sur
p
ression hall (CAST)
I Highaserecor=nnnrn,s~nnnrnn'nc,~Ia:pr<mnj- ccmpesr,.
Ideally . °907 of paienu ovuM have : a090 11-11111-n Cf I'll -11T
mamrc cnmptcxes and Odo'l wppressgn of,'entscslar tachycardia
al Iak,,,i d derears
'. High dcsrec of lot.nose zsosl of remu s having n. h,, hmia
nnpp~cserd and totrnoeoe its died rwr _ . r~
I InY.qurnl dozing
a
. IaGccucni xdvu, pmarrhyIhmia
5 . Infrequent serious noncardiac adverseeffects
5. E .nensive experience in posaavecard .1 in-tin nations in In
v ocular 0.10gb aai„hy
7 . Eaeaiee in ether padeo gowns
s . Suitable tar a multiple dose . multiple drip bladed aai
9. Marketed o. ..n w be marketed in the United States
10. Mialmal nsxanive inarupic arms
l I . No dnrg intaraeliens lsnecifi :ally . ,ith digaahs and beta sdre,ery e
bleeheg
agents)
I :. Uniform dosing [minimal dose changes required in paients with trait
failure . renal failure. liver railon, to, exatllplel
13 No additional nonantiarrbSannnt unions Ifor example, intrinsic beta-
adrenergic Mnckader
IA. Efcacicuve,judsedb• elrerrnpM1ym,k,gewwdy(a::vs.igh
nleco-nphI,ioiegic >wdy soil would oNt be read in die CASTT
The "Standard" to Drugs
None of the commonly prescribed "su.ndard" antiar-
rhythmic agents was deemed acceptable for inclusion in the
CAST. Inadequate suppression of ventricular premature
complexes or unknown degree of suppression of ventricular
premature complexes characterized most drugs considered .
Quinidine . This drug has a predictably high (approxi-
mately 30%) early drnnnnt rate doe to gasrrninteslinat and
other toxic effects (5-6) and thus would not achieve the
CAST goal of =g0% suppression of ventricular premature
complexes and >90% suppression of ventricular tachycardia
maintained in at least 80%n of patients at 1 year. Additionally,
published estimates of pruarrhythmia (including tursade de
pointes) ranged from 0.5 to 2°% (7,g) . These data heightened
concern about initiating this ding for prophylaxis against
sudden death in a large number of outpatients with asymp-
tomatic "potentially lethal
--
venrricutar urrhythmios, even
though the proarrhythmic effect of quinidiue may be no
worse than that of many other drugs . 'the quinidine-digoxin
interaction would also complicate a double-blind trial,
Proeainamide . This drug was considered of limited 'use
for widespread secondary prevention because of the need for
four times daily dosing and the high incidence of ding-
induced lupus erylhemalosus (positive antinuclear antibody
in 60% to 70% and topes symptoms in
2(110% l0% of
panic nts
at I year). In a previous secondary prevention trial by
Kosowsky et al,
(9),
2390 of subjects discontinued therapy
within 3 months and 41% terminated use of the drug before
completion of the 2-year study . Of additional concern were
the reports of procainamide-associated blood dyscrasias,
estimated to be as high as 0,5%, which would require weekly
blood counts for 12 weeks .
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Disopyramide. This drug also had been studied previ-
ously in postmyocardial infarction secondary prevention
trials (10-12) without evidence of benefit. In 610 patients
combined from three studies, the mortality rate was 8 .6%
with the active drug versus 8 .8% with placebo, Other limi-
tations or disopyramide included potential aggravation of
congestive heart failure in patients with a low ejection
traction and bothersome anticholinergic side effects in l0%a
to 40% that often led to withdrawal from therapy .
The Class IB Drugs
Tacar,ide and mexiletine . Neither of the class IF antiar-
rhythmic agents, tocainide and mexiletine, had demon-
strated promise for preventing sudden death in earlier post-
myocardial infarction secondary prevention trials (13-16),
nor were they very effective in suppressing ventricular
premature complexes . Although
these
trials had not selected
subjects for the presence of ventricular premature com-
plexes and had not assessed suppression of ventricular
eceopic activity, the dropout rate due to gastrointestinal and
central nervous system toxic effects was high, and no
favorable survival trends were noted . In fact, a [rend toward
increased mortality was seen with mexiletine in the largest
trial, the International Mexiletine and Placebo Antiarrhyth-
raic Coronary Trial (I6), which tested mexiletine versus
placebo. This trial observed a I-year mortality rate of 7.691
with mexiletine versus a 4 .8% rate in the placebo group (p =
NS) . These results were consistent with the many reports
117,18) demonstrating that class IB drugs achieved only
moderate suppression of
ventricular premature complexes
as assessed by Holier monitor and poor suppression of
ventricular tachycardia on electrophysiologic study . Fur- .
thermore, rocninide, like procainamidc, was considered to
have an unacceptable safely profile because ;t rarely induced
granulocytopcnia .
Cnmhlnmton of quinidine and mexiletine. This combioa-
tion had several merits for consideration for use in the
CAST
. When used in combination, each agent can be
administered in lower doses, decreasing intolerable side
effects while enhancing efficacy (19) . Reports of succe ss with
quinidine plus mexiletine have been encouraging with both
Holterguided therapy and electrophysiologic testing (19,20)
.
Enthusiasm for this drug combination was guarded, how-
ever, because of the rather small data base (<400 patients in
published reports on this regimen and <100 patients fol-
lowed up for >1 year) and the undesirable complexity of
using two drugs in a CAST population
. The proarrhythmic
potential of quinidine and its interaction with digoxin also
decreased the desirability of this combination .
Other Drags
Amiudarnne. The well established toxicity or amio-
darone, especially pulmonary fibrosis, diminished enthusi-
asm for its use in this asymptomatic patient group . Further-
JACC Vot, 19 . No . 5
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more, its complex pharmacokinetics and its interaction with
digoxin and warfarin made it undesirable for use in this
blinded trial .
Propafenone . This class 1C drug with a data base of
nearly [,000 patients (Knoll Pharmaceuticals) appeared to
have good suppression of ventricular premature complexes
and tolerance . However, the dose-response relation for
arrhythmia suppression was not defined, and patients could
be either slow or fast memholizers with different rates of
response and side effects (21). Long-term drug efficacy and
safety information were somewhat limited, and the potential
beta-adrenergic blocking effect (22) would have confounded
the ability to test the hypothesis of suppression of ventricu-
lar premature complexes . Any reduction in mortality ob-
served could possibly have been due to beta-adrenergic
blockade and unrelated to suppression ofventricula prema-
ture complexes .
Other investigatlonal drugs . These drugs (pirmenol,
cibenzoline, indecainide, somlol, d-sotalol, bepridil, lorcain-
ide. n-acetylprocainamide) were excluded for a variety of
reasons, primarily limited patient exposure with an inade-
quatedata base for safety and efficacy in a CAST population,
even though sonic were thought to be promising new agents .
Rafionate for Encainide, Flecainide and
MorictZine in the CAST
The four drugs tested in the earlier Cardiac Arrhythmia
Pilot Study (CAPS) (23) were reassessed for inclusion in the
CAST . In the CAPS, imipramine caused only limited sup-
pression of ventricular premature complexes (52%) and had
a high rate (2624) of anaccep
;able side effects, particularly
pnopnat hypotensiun, and thus was eliminated as a candi-
date for the CAST. Both class IC drugs, encainide and
flecainide, had achieved the goal of a7o% suppression of
vemricular premature complexes in the CAPS in 79% and
83% of patients, respectively . The incidence of intolerable
side effects for encainide (5%) and flecainide (5%) was
comparable to that of placebo (3%).
Proarrhythmia did not
appear excessive during I year of follow-up (encainide 1%,
flecainide 3%, placebo 3%)
. Large data bases (albeit not for
patients in the immediate posimyocardial infarction period)
were available for both encainide and flecainide . The fourth
CAPS drug, moricizine, afforded satisfactory efficacy (66%
of patients showed a70% suppression of ventricular prema-
ture complexes) although the rate of suppression was slightly
lower than that or Iecainide or encainide
. The pharmaceu-
tical manufacturers data base For moricizine (E .1 DuPont
deNemours) included 1,190 patients with good drug toler-
ance and there was a low incidence of proarrhythmia and
congestive heart failure .
Deaths and proarrhythmia were infrequent in the CAPS
(13). Congestive heart failure requiring hospitalization up-
reared to occur slightly more frequently in flecainide-treated
patients (20% taking flecainide, 6% taking encainide, 10%n
taking placebo) (24) .
This finding in the CAPS prompted
JACC Vol19,N,.5
199 :,694-8
CAST investigators to restrict the use of flecainide to
patients with an ejection fraction ?0 .30 (24 .25). Patients
with such an ejection ilaciton were randomized to either
1) flecainide, then moricizine and then encainide, or
2) encainide, then moricizine and then flecainide . The two
class IC autiarrhylhmic agents. encainide and flecainide,
were always given first because these agents seemed to he
better at suppressing ventricular premature complexes .
Treatment proceeded from one drug to the next arty if
ventricular premature complexes were not suppressed by
the highest dose of drug or if adverse effects occurred . For
patients with an ejection fraction X0
.30, the drug sequence
was either 1) encainide then moricizine
. or 2) moricizine and
then encainide
. The study was thus designed to identify
suppression of ventricular premature complexes at the ear-
liest possible lime, both for simplicity of protocol and for
case of patient recruitment and compliance.
Though both class IC drugs, encainide and flecainide, had
been marketed for only I to 2 years at the initiation of the
CAST and moriciz
:s a had not received approval of the Food
and Drug Administration, these agents appeared to have the
most favorable overall profile for application in the CAST
protocol.
Implications of the Open Label Drug
Titration Design
Because the study was designed as a suppression trial, an
attempt was made to identify rapidly a drug that would
suppress ventricular premature complexes for each individ-
ual patient . In the CAST, the dose titration phase of the
study was not placebo-controlled . The incidence of arrhyth-
mia aggravation during the CAPS dose titration phase (ap-
proximately 2 weeks) and, in particular, during the initial
2-day inpatient treatment initiation phase in the CAPS, was
very low (1% tc 3%) and was similar in all treatment groups,
including the placebo group
. Furthermore, this arrhythmia
aggravation in the CAPS consisted almost exclusively of
asytnptomatic increases in frequency of ventricular prema-
ture complexes . Therefore, in the CAST hospitalization was
not required for initiation of treatment, The CAST included
higher risk subgroups, such as those with ejection fraction
<0S0 or bundle branch block . Investigators recognized that
having an open label titration phase at the beginning of the
study could result in mortality or side effects during the
titration phase that could not be interpreted because no
placebo control was included at this time . However, because
of the need to identify a srccessful drug rapidly, this
trade-off was accepted.
Only after reach patient was identified as a "responder"
was the patient randomized to either the successful drug or
its placebo. Patients with partial (1% to 79%) suppression of
ventricular premature complexes entered a substudy.
nREENE ET AL.
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Initial Results of the CAST
Encainide and Iecainide . Randomiration in the CAST
began in time 1987- Most patients (75%0) achieved satisfac-
tory suppression o€ ventricular premature complexes, 52%
with the first dose of the first drug
. In April 1989, encainide
and flecainide were removed From the CAST t26). A total of
1 .498 patients had hunts randomized either to encainide or
flecainide or to their placebos. A! that lime, the study
determined that both total cardiac mortality and deaths from
arrhythmias were increased in the groups treated wits
ene'
.imde or decai side (t) .
! .tarieiaine . Only a relatively small number of patients
had actually been randomized to moricizine or its placebo
(1 -1 , as cf Anril 1989) for two reasons : I) moricizine was the
second drug in the segn_nce for patients with an ejection
fraction =0 .30 . but encainide and iecainide were so success-
ful in suppressing ventricular premature complexes that very
few patients were exposed to moricizine in this high ejection
traction group ; and 2) equal numbers of patients were
randomized to encainide or morrizine among those with an
ejection fraction 00.30, but fewer patielet qualified in this
category.
The beta and Safety Monitoring Board and the National
Institutes of Health enthusiastically endorsed continuation
of the CAST with moricizine, the continuation of the study
called the Cardiac Arrhythmia Suppression Trial-If (CAST-
It) .
Impact of the Initial CAST Results and
Design of CAST-II
The preliminary results of the CAST in patients with
at)oeardial infarction established that either the hypothesis
of suppression of ventricu'rar premature complexes was
invaliu or that it may be drug specific- It is unknown whether
the CAST findings apply only to patients who have recently
survived a myocardial infarction, The mechanisms an also
unknown--presumably interactions among an antiarrhylh-
mic drug, myocardial scar and some intercurrent factor,
such as ischemia or infarct healing .
Because of these results, encainide and flecamide were
removed from the CAST. Consideration was given to the
addition of another drug or drugs . Becau se no drug met the
original acceptability criteria, and because it would have
been logistically difficult to add another drug, the CAST-It
continued with mncmziae onth. After April 1989, sseveral
other major changes were made in the protocol for the CAST
that continued as the CAST-ti (Table 2) . Because no sudden
arrhythmic deaths occurred in the patients enrolled late alter
their myocardial infarction, the enrollment time was limited
to 4 to 9o days after myocardial infarction . Similarly, the
qualifying cjeuriun F cticn was lowered to -o .aa. Tn at-
tempt to achieve a higher rate of suppression of ventricular
premature complexes, a higher dose of moricizine was
allowed. Patients formerly treated with encainide or 0ecain-
855
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Table A Major Changes in CAST Protocol for Continuation
as CAST11
L Encainide and ttooiaide were tcmoscd : no raw drugs were added
2 . Curlifying elector fmetfrn was educed to s0.40
1 . Enrollment lime was changed In 4 m 90 day, after myocardial infuration
4, A higher dose of moriciare tnod
.gay)as
added
5 . Titrstinn phase was drab'x card with a placebo to detect adverse
evemsldeaths diving tinadon
Q Definition ofdisgmdify'ine ventricohd lachycardia was changed to a30 s
at a rare of 0111 healslmin or ventricular mchyeardie thm was
"raptmral Ic
ide (or with encainide placebo or flecainide placebo) could he
rerandomi zed if they met the new entry critet is (except for
the criterion of lime since myocardial infarction) . The titra-
tion phase of the CAST-11 study was placebo controlled to
determine if there was a mortality benefit (or risk) during the
1st 2 weeks of exposure to drug .
Jxloricizlne . The results of the CAST-11 evaluated the
utility of ventricular premature complex suppression with
moricizine after myocardial infarction. Initial exposure to
moricizine yielded a higher mortality rate than that of initial
exposure to placebo . In addition, the long-term phase
of the
study was unlikely to slow any survival benefit from treat-
ment with the drug (CAST Investigators, unpublished obser-
vations)
. Thus, the ventricular premature complex hypoth-
esis was disproved, and we concluded that patients with
ventricular premature complexes after myocardial infarction
should not be Inutincly treated with antiarrhylhmic agents .
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